Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMUX Immunic	$0.82 -5.7%	$0.87	$0.56 ▼ $2.11	$80.89M	1.39	1.23 million shs	1.12 million shs
OVID Ovid Therapeutics	$1.27 +1.5%	$0.59	$0.24 ▼ $1.47	$90.24M	0.2	1.01 million shs	1.12 million shs
QNCX Quince Therapeutics	$1.62 +5.1%	$1.66	$0.66 ▼ $2.45	$86.96M	1.02	231,574 shs	198,337 shs
SNYR Synergy CHC	$2.40 +13.2%	$3.24	$1.30 ▼ $10.00	$22.66M	N/A	452,667 shs	211,286 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMUX Immunic	+2.35%	-7.93%	-11.16%	+32.00%	-38.30%
OVID Ovid Therapeutics	-0.79%	+30.62%	+131.35%	+346.43%	-2.34%
QNCX Quince Therapeutics	-1.28%	-4.35%	-8.33%	+49.51%	+134.94%
SNYR Synergy CHC	+1.44%	-26.90%	-41.76%	+23.26%	+2,020.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMUX Immunic	2.7028 of 5 stars	3.6	1.0	0.0	3.1	2.5	0.6
OVID Ovid Therapeutics	4.2072 of 5 stars	3.6	3.0	4.6	2.3	2.5	0.0
QNCX Quince Therapeutics	3.8843 of 5 stars	4.6	3.0	0.0	4.0	1.7	0.6
SNYR Synergy CHC	4.3746 of 5 stars	3.8	0.0	0.0	3.1	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMUX Immunic	3.29	Buy	$7.50	814.63% Upside
OVID Ovid Therapeutics	3.17	Buy	$3.10	144.29% Upside
QNCX Quince Therapeutics	3.18	Buy	$8.14	402.96% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	316.67% Upside

Current Analyst Ratings Breakdown

Latest SNYR, IMUX, OVID, and QNCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
8/12/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$9.00 ➝ $8.00
8/8/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/8/2025	OVID Ovid Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/5/2025	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/5/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00
8/5/2025	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$9.00
7/17/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/13/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMUX Immunic	N/A	N/A	N/A	N/A	$0.34 per share	N/A
OVID Ovid Therapeutics	$570K	158.31	N/A	N/A	$0.78 per share	1.63
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
SNYR Synergy CHC	$34.83M	0.65	$0.31 per share	7.86	($1.31) per share	-1.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-461.46%	-217.16%	11/6/2025 (Estimated)
OVID Ovid Therapeutics	-$26.43M	-$0.53	N/A	N/A	N/A	-574.44%	-58.87%	-43.18%	11/11/2025 (Estimated)
QNCX Quince Therapeutics	-$56.83M	-$1.09	N/A	N/A	N/A	N/A	-187.49%	-42.47%	11/12/2025 (Estimated)
SNYR Synergy CHC	$2.12M	$0.38	6.32	4.07	N/A	10.02%	-18.56%	20.28%	N/A

Latest SNYR, IMUX, OVID, and QNCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SNYR Synergy CHC	$0.08	$0.17	+$0.09	$0.17	$10.80 million	$6.74 million
8/13/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	-$0.06	+$0.10	-$0.06	$0.09 million	$6.27 million
8/11/2025	Q2 2025	QNCX Quince Therapeutics	-$0.28	-$0.34	-$0.06	-$0.34	N/A	N/A
8/7/2025	Q2 2025	IMUX Immunic	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMUX Immunic	N/A	2.19	2.19
OVID Ovid Therapeutics	0.23	4.72	4.72
QNCX Quince Therapeutics	1.45	5.00	5.00
SNYR Synergy CHC	N/A	2.74	2.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMUX Immunic	51.82%
OVID Ovid Therapeutics	72.24%
QNCX Quince Therapeutics	30.75%
SNYR Synergy CHC	N/A

Insider Ownership

Company	Insider Ownership
IMUX Immunic	4.60%
OVID Ovid Therapeutics	13.10%
QNCX Quince Therapeutics	20.30%
SNYR Synergy CHC	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMUX Immunic	70	98.65 million	94.11 million	Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
QNCX Quince Therapeutics	60	53.71 million	42.81 million	Optionable
SNYR Synergy CHC	40	9.44 million	4.10 million	N/A

SNYR, IMUX, OVID, and QNCX Headlines

Recent News About These Companies

Reviewing Synergy CHC (NASDAQ:SNYR) & Grove Collaborative (NYSE:GROV)

August 29 at 4:11 AM | americanbankingnews.com

Synergy CHC Completes $4.375M Public Offering

August 27 at 5:30 PM | tipranks.com

Synergy CHC Corp. Announces the Closing of its $4.375 Million Public Offering

August 27 at 4:15 PM | globenewswire.com

Synergy CHC (SNYR) & The Competition Financial Comparison

August 26 at 4:35 AM | americanbankingnews.com

Synergy CHC 1.75M share Secondary priced at $2.50

August 26 at 3:19 AM | msn.com

Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering | SNYR Stock News

August 25, 2025 | gurufocus.com

Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering of Common Stock

August 25, 2025 | quiverquant.comQ

Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering

August 25, 2025 | globenewswire.com

Synergy CHC's (NASDAQ:SNYR) Earnings Quality Is Low

August 22, 2025 | finance.yahoo.com

Synergy CHC Corp to Present at the 2025 Gateway Conference on September 4th

August 21, 2025 | markets.businessinsider.com

New to The Street’s Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S ...

August 20, 2025 | palmbeachpost.comP

Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + Energy

August 18, 2025 | taiwannews.com.twT

New to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...

August 18, 2025 | finanznachrichten.de

Synergy CHC announces major distribution with for FOCUSfactor Focus + Energy

August 18, 2025 | msn.com

Synergy CHC Expands FOCUSfactor Distribution with EG America

August 18, 2025 | tipranks.com

Analysts Set Expectations for Synergy CHC FY2025 Earnings

August 18, 2025 | americanbankingnews.com

Synergy CHC files to sell 1.28M shares of common stock

August 15, 2025 | msn.com

Synergy Chc EPS Jumps 86 Percent in Q2

August 15, 2025 | theglobeandmail.com

Synergy CHC Corp.: Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

August 14, 2025 | finanznachrichten.de

Synergy CHC reports Q2 EPS 17c vs 9c last year

August 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SNYR, IMUX, OVID, and QNCX Company Descriptions

Immunic NASDAQ:IMUX

$0.82 -0.05 (-5.75%)

Closing price 03:59 PM Eastern

Extended Trading

$0.83 +0.01 (+0.98%)

As of 04:12 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Ovid Therapeutics NASDAQ:OVID

$1.27 +0.02 (+1.52%)

Closing price 03:59 PM Eastern

Extended Trading

$1.25 -0.02 (-1.89%)

As of 04:10 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Quince Therapeutics NASDAQ:QNCX

$1.62 +0.08 (+5.13%)

Closing price 03:59 PM Eastern

Extended Trading

$1.60 -0.02 (-1.48%)

As of 04:10 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Synergy CHC NASDAQ:SNYR

$2.40 +0.28 (+13.21%)

As of 03:50 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time